Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Combined Synopsis/Solicitation opportunity from Department Of Health And Human Services was posted on August 13, 2024. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

LIFE TECH EXPIFECTAMINE 293 TRANSFECTION KIT (AMBIS 2228842)

Closed
RFQ-NIAID-24-2228842Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325413
New
Federal
Cost Per Reportable Result Purchase of Immunohistochemistry Reagents for Laboratory Tests.
Solicitation # 36C26027Q0058
The Department of Veterans Affairs, through Network Contracting Office 20, is seeking a comprehensive histology staining workflow system for the Puget Sound Health Care System in Seattle, Washington. The required system must include two immunohistochemistry and two in-situ hybridization immunostainers, two special stainers, and an integrated specimen tracking system to ensure patient safety, maintain a chain of custody, and monitor productivity. The workflow components must be fully automated, communicate with one another, and maintain compatibility with Data Innovations middleware as well as VISTA, Cerner, and any future electronic health record systems acquired by the VA. The contract follows a Cost Per Reportable Result pricing model and spans a base year from February 1, 2027, to January 31, 2028, with four subsequent one-year option periods extending through January 31, 2032. Technical requirements specify that the immunostainers must perform 100% of tests listed in the provided specifications and support simultaneous IHC, ISH, and Direct Immunofluorescence staining. Equipment must support Code 39 and Code 128 barcodes, include a safe hazardous waste removal system, and be provided with an uninterruptible power supply capable of supporting a 15-minute controlled shutdown. The contractor is responsible for the delivery, installation, and removal of equipment at no additional charge and must guarantee a minimum equipment uptime of 98%. Performance and method validation must adhere to CLSI guidelines and College of American Pathologists standards. Additionally, the contractor must comply with strict federal and VA information security directives, including those regarding data confidentiality and media sanitization. Emergency supply orders must be fulfilled within 24 hours of a verbal request, providing enough consumables for one week of normal operation.
260-NETWORK Contract Office 20 (36C260)

POSTED

1 day ago

DEADLINE

in 24 days
NAICS: 325413
New
Federal
6550--HEMOCHRON SIGNATURE ELITE REAGENTS AND SUPPLIES
Solicitation # 36C26227Q0046
The Department of Veterans Affairs, Network Contracting Office 22, is conducting a sources sought notice for the procurement of FDA approved reagents, supplies, consumables, and quality control materials for Werfen Hemochron Signature Elite instruments. This requirement supports the Pathology and Laboratory Medicine Service at the Southern Arizona VA Health Care System in Tucson, Arizona. The contract structure includes a base year from January 1, 2027, to December 31, 2028, followed by four subsequent option years extending through December 31, 2032. The selected contractor must provide 24/7 technical and product support at no additional cost and ensure all items are fully compatible with existing instrumentation without requiring workflow changes or retraining. Key operational requirements include strict adherence to manufacturer specifications for packaging and temperature control during transport. All supplied materials must maintain a minimum shelf life of 90 days, and shipments must clearly list lot numbers and expiration dates. Standard orders are required to be delivered within four working days, while emergency deliveries for defective or temperature-compromised items must be completed within 24 hours of a verbal order. This procurement is conducted as a brand name or equal acquisition under FAR 52.211-6. Interested respondents must provide their business size status, SAM.gov identifiers, and evidence of compliance with the Buy American Act and the Non-Manufacturer Rule.
262-NETWORK Contract Office 22 (36C262)

POSTED

3 days ago

DEADLINE

in 13 days

General Info

Contract Value

$51,260.8

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Award Issued Date

Documents

1

Terms and Conditions RFQ-NIAID-24-2228842 (FAR 52.212-5)

PDF, High priority: read this firstcontract-document
High

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseClosed
Posted

Combined Synopsis

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid
Contacts2 people available
OfficeBETHESDA, MD, 20892, USA

Full Description

Show more
This notice is a Combined Synopsis/Solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 - Streamlined Procedures for Evaluation and solicitation for commercial Items, as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. The Solicitation number is RFQ-NIAID-24-2228842 and the solicitation is issued as a Request for Quotes (RFQ). This acquisition will be processed under FAR Part 13 Simplified Acquisition Procedures (SAP). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2024-05, May 22, 2024. The North American Industry Classification System (NAICS) code for this procurement is 325413, In-Vitro Diagnostic Substance Manufacturing, with a size standard of 1250 employees. The requirement is being competed with a brand name restriction, and without a small business set-aside. The National Institute of Allergy and Infectious Diseases (NIAID) has a requirement for the following Brand Name Supplies: 1. ExpiFectamine 293 Transfection Kit, 10L, Product #: A14525, qty 8 each 2. Shipping and Handling, qty 1 each The Vaccine Research Center (VRC) is to provide a mechanistic basis for developing preventive vaccines against HIV, malaria, tuberculosis, SARS-CoV2 and therapeutic vaccines against cancer. The project aims to harness the Expi Transfection System for advanced vaccine research, focusing on accelerating the development and optimization of novel vaccine candidates. This system is integral for the production of high-yield, high-quality recombinant proteins and viral vectors, essential components in vaccine development. Thermo Fisher Scientific's proprietary technology and formulations are specifically designed to work together, providing a comprehensive and efficient solution for high-yield protein production essential for vaccine research. The use of these specific products is critical to achieving the project's objectives with unique and essential characteristics, ensuring the success of the vaccine research project through optimized, high-efficiency, and scalable protein production. In order for continuity of our research efforts the ExpiFectamine 293 Transfection Kit is being requested, which to change would be very costly to the government. Place of Performance: NIH, NIAID, VRC, 40 Convent Drive, Bethesda, MD 20892, United States. FOB: Destination The government intends to award a firm fixed price purchase order to the responsible contractor as a result of this RFQ that will include the terms and conditions set forth herein. The award will be based on the following: technical capability to meet the requirements, price, and delivery. By submitting a quote in response to this solicitation, vendor is accepting the following terms and conditions: The following FAR provisions apply to this acquisition: FAR 52.212-1 Instructions to Offerors Commercial Items (SEP 2023) FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (MAY 2024) FAR 52.204-7 System for Award Management (OCT 2018) (Offerors must complete annual representations and certifications on-line at http://www.sam.gov/ in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items (Please ensure FAR 52.209-2 -- Prohibition on Contracting with Inverted Domestic Corporations--Representation. (Nov 2015) is updated in your SAM record) FAR 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements - Representation (JAN 2017) FAR 52.204'26 Covered Telecommunications Equipment or Services-Representation (OCT 2020) *** Must complete representation if attached to this solicitation- see attachment 52.204-26 The following FAR contract clauses apply to this acquisition: FAR 52-212-4 Contract Terms and Conditions Commercial Items (NOV 2023) FAR 52-212.5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (MAY 2024) *The applicable subparagraphs of FAR52.212-5 are included in the attachment to this posting. FAR 52.232-40 Providing Accelerated Payments to Small Business Subcontractors (MAR 2023) FAR 52.204-13 System for Award Management Maintenance (OCT 2018) FAR 52.204-25 Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment (NOV 2021) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (DEC 2015) 52.252-2 -- Clauses Incorporated by Reference. (FEB 1998) This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this address: http://farsite.hill.af.mil/vffara.htm By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the System for Award Management (SAM) database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation (www.sam.gov). Copies of the above-referenced provisions and clauses are available from http://www.acquisition.gov/far/loadmainre.html & http: //www.hhs.gov/regulation/index.html or, upon request, either by telephone or fax. Submission shall be received not later than Friday, August 23, 2024 @ 11:00 AM EST All quotations and required documents must be submitted via the NIAID electronic Simplified Acquisition Submission System (eSASS) website at https://esass.nih.gov. All vendors must register in the eSASS system to submit a quotation. Instructions on how to register / submit quotes are included on the website. Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f). All responsible sources may submit an offer that will be considered by this Agency.

More opportunities from Department Of Health And Human Services → National Institutes Of Health Niaid

Same awarding agency

NAICS: 541715
Federal
2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases
Solicitation # HHS-NIH-NIAID-BAA2026-1
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals under Broad Agency Announcement HHS-NIH-NIAID-BAA2026-1 to advance the research and development of medical interventions for infectious diseases. This initiative focuses on three primary research areas: the development of needle-free vaccine candidates through early-phase clinical trials; the creation of safe and effective therapeutic candidates for serious infectious diseases, including those resistant to current antimicrobial therapy; and the innovation of in vitro diagnostic technology platforms capable of rapid, automated detection of a broad panel of priority viral pathogens. The program emphasizes alignment with NIH priorities regarding biosafety, biosecurity, and the use of non-animal testing methods. Proposals must be submitted electronically via the NIAID eCPS website by December 8, 2026, at 3:00 PM Eastern Time. Technical proposals are limited to 75 pages and will be evaluated by a peer review group based on technical merit, with the technical plan and personnel qualifications being of paramount consideration. Awards are not based on a common Statement of Work; instead, offerors must propose their own technical plans, milestones, and cost structures using a base and option period format. The resulting contracts will require an accounting system compliant with generally accepted accounting principles and will involve rigorous government inspection and acceptance based on the successful completion of critical milestones.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

12 days ago

DEADLINE

in about 2 months
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS